Analysis Of The Effect Of Non-steroidal Aromatase Inhibitor On Blood Lipid Level In Patients With HR Positive Breast Cancer After Operation

Objective:To observe the effect of non-steroidal aromatase inhibitors on blood lipid level in postmenopausal patients with hormone receptor positive breast cancer,and to explore how to select endocrine drugs in clinical practice to reduce the adverse reactions of dyslipidemia and metabolism in postmenopausal patients with hormone receptor positive breast cancer.Further prevent and reduce the occurrence of cardiovascular events,so as to achieve longer survival time.Methods:A total of 104 patients with breast cancer who underwent breast cancer surgery in the first affiliated Hospital of Dalian Medical University from January 1,2009 to December 31,2015 were collected by electronic medical record system.According to the patient's condition,the comprehensive treatment methods of postoperative adjuvant chemotherapy,radiotherapy,endocrine therapy and targeted therapy were selected.Endocrine therapy was carried out in the Department of Oncology,the first affiliated Hospital of Dalian Medical University.The selected endocrine drugs were non-steroidal aromatase inhibitors(AI): letrozole and anatrazole,which were completed for at least 3 years.The changes of low density lipoprotein(LDL-C),total cholesterol(TC),high density lipoprotein(HDL-C)and glycerate(TG)in the first year,the second year and the third year of treatment were analyzed.To analyze the changes of blood lipid in patients with hyperlipidemia after application of AI class,and to analyze the changes of blood lipid level between letrozole and anatrazole groups.Results:1.Letrozole group:the level of LDL-C: was significantly higher than the baseline,especially in the second year of treatment,which reached the peak(2.4%).TC:During the treatment,the level of TC was higher than the baseline,and the difference was not statistically significant.HDL-C: With the prolongation of medication time,the level of HDL-C decreased significantly compared with the baseline.especially in the third year of medication,the decrease was 12.69%.TG:With the prolongation of medication time,TG was significantly higher than the baseline,the difference was statistically significant,especially in the third year of medication,increased by 10.26%.2.Anatrazole group:LDL-C and TC: with the prolongation of medication time,they were increased significantly,the difference was statistically significant,especially in the third year of treatment,the increase was 4.56% and 2.07%,respectively.During thetreatment period of HDL-C:the level was higher than the baseline,and the difference was not statistically significant.TG: With the prolongation of medication time,the level lower significantly than the baseline,especially in the third year of medication reached the peak,decreased by 10.30%.3.The comparison between letrozole and anatrazole group:the period of treatment in LDL-C and TC: anatrazole group was lower than letrezole group,and there was no significant difference between the two groups.HDL-C:anatrazole group was significantly higher than letrezole group,especially in the third year,which was 14.53% higher than letrezole group.TG: anatrazole group was significantly lower than letrezole group,especially in the third year of treatment,which was 13.95% lower than letrezole group.4.Patients with hyperlipidemia were treated with letrozole and anatrazole Taking letrozole and anatrazole for 3 years after operation had little effect on blood lipid metabolism,but there was no significant difference in P value.Conclusion:1.Long-term administration of letrozole and anatrazole can cause abnormal levels of blood lipid metabolism,but the effects of letrozole and anatrazole on different lipid metabolism are different.2.The effect of long-term administration of anatrazole on the metabolism of some blood lipids in patients was less than that of letrozole.